Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
======================================================================================================================================================

* Eunhee Lee
* Shinai Lee
* Sumyeong Park
* Yong-Gyu Son
* Jiseon Yoo
* Youngil Koh
* Dong-Yeop Shin
* Yangmi Lim
* Jonghwa Won